Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly insulin icodec versus once-daily insulin glargine in insulin-naive adults with type 2 diabetes mellitus
MOH_2020-09-02_009111Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised trial in type 2 diabetes mellitus (T2DM) comparing Insulin icodec plus non-insulin antidiabetic therapy with Insulin glargine plus non-insulin antidiabetic therapy (2 arms). Started Aug 2020; status: completed.
02
Drugs
insulin icodecinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on MOH_2020-09-02_009111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-09-02_009111.